Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Freeline Therapeutics Holdings (FRLN)
NASDAQ:FRLN
RESEARCH TOOLSreports
Holding FRLN?
Track your performance easily
FRLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.11 - $8.70
Previous Close$6.48
Volume5.66K
Average Volume (3M)25.68K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$47.28M
Total Debt (Recent Filing)$5.92M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 28, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,340,905
10 Day Avg. Volume39,933
30 Day Avg. Volume25,677
Standard Deviation0.19
R-Squared0.03
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)7.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$6.50Price Target Upside0.31% Upside
Rating ConsensusHold
Number of Analyst Covering2
Freeline Therapeutics Holdings News
PremiumPress Releases
Syncona to Acquire Freeline Therapeutics
Ownership Overview
0.00%
Insiders
0.39% Mutual Funds
4.22% Other Institutional Investors
95.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FRLN FAQ
What was Freeline Therapeutics Holdings’s price range in the past 12 months?
Freeline Therapeutics Holdings lowest stock price was $2.11 and its highest was $8.70 in the past 12 months.
What is Freeline Therapeutics Holdings’s market cap?
Currently, no data Available
When is Freeline Therapeutics Holdings’s upcoming earnings report date?
Freeline Therapeutics Holdings’s upcoming earnings report date is Mar 28, 2024 which is 239 days ago.
How were Freeline Therapeutics Holdings’s earnings last quarter?
Freeline Therapeutics Holdings released its earnings results on Nov 07, 2023. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.04.
Is Freeline Therapeutics Holdings overvalued?
According to Wall Street analysts Freeline Therapeutics Holdings’s price is currently Undervalued.
Does Freeline Therapeutics Holdings pay dividends?
Freeline Therapeutics Holdings does not currently pay dividends.
What is Freeline Therapeutics Holdings’s EPS estimate?
Freeline Therapeutics Holdings’s EPS estimate is -$0.26.
How many shares outstanding does Freeline Therapeutics Holdings have?
Freeline Therapeutics Holdings has 4,357,933 shares outstanding.
What happened to Freeline Therapeutics Holdings’s price movement after its last earnings report?
Freeline Therapeutics Holdings reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went down -5.298%.
Which hedge fund is a major shareholder of Freeline Therapeutics Holdings?
Among the largest hedge funds holding Freeline Therapeutics Holdings’s share is Woodline Partners LP. It holds Freeline Therapeutics Holdings’s shares valued at N/A.
---
Freeline Therapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.50 (0.31% Upside)
$6.50 (0.31% Upside)
Hedge Fund Trend
Decreased
By 1.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-101.55%
Trailing 12-Months
Asset Growth
-50.82%
Trailing 12-Months
Company Description
Freeline Therapeutics Holdings
Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.
---
FRLN Stock 12 Month Forecast
Average Price Target
$6.50
▲(0.31% Upside)
Technical Analysis
Best Analysts Covering FRLN
1 Year
---